Abstract
Standard-of-care management of renal cell carcinoma (RCC) indisputably relies on surgery for low-risk localized tumours and systemic treatment for poor-prognosis metastatic disease, but a grey area remains, encompassing high-risk localized tumours and patients with metastatic disease with a good-to-intermediate prognosis. Over the past few years, results of major practice-changing trials for the management of metastatic RCC have completely transformed the therapeutic options for this disease. Treatments targeting vascular endothelial growth factor (VEGF) have been the mainstay of therapy for metastatic RCC in the past decade, but the advent of immune checkpoint inhibitors has revolutionized the therapeutic landscape in the metastatic setting. Results from several pivotal trials have shown a substantial benefit from the combination of VEGF-directed therapy and immune checkpoint inhibition, raising new hopes for the treatment of high-risk localized RCC. The potential of these therapeutics to facilitate the surgical extirpation of the tumour in the neoadjuvant setting or to improve disease-free survival in the adjuvant setting has been investigated. The role of surgery for metastatic RCC has been redefined, with results of large trials bringing into question the paradigm of upfront cytoreductive nephrectomy, inherited from the era of cytokine therapy, when initial extirpation of the primary tumour did show clinical benefits. The potential benefits and risks of deferred surgery for residual primary tumours or metastases after partial response to checkpoint inhibitor treatment are also gaining interest, considering the long-lasting effects of these new drugs, which encourages the complete removal of residual masses.
Key points
-
Peri-operative targeted therapy for high-risk localized renal cell carcinoma (RCC) has not shown real benefits in terms of overall survival and is not recommended in current clinical practice.
-
Neoadjuvant treatments have been reported to result in tumour downstaging, but never became a standard of care owing to a lack of evidence of cancer-specific and overall survival improvement, and a small number of patients. Results from trials in which the efficacy and safety of neoadjuvant immunotherapies and combined treatments will be assessed in patients with RCC are awaited.
-
Peri-operative immunotherapies in locally advanced RCC are gaining interest. Promising outcomes with adjuvant pembrolizumab were reported in 2021 and results from other trials are awaited.
-
Upfront cytoreductive nephrectomy is not considered the standard of care any longer, but might remain beneficial for a subset of patients with favourable disease characteristics (good performance status, single-site tumour, oligometastatic disease and only one International Metastatic RCC Database Consortium criterion).
-
Deferred surgery might be an option in selected patients who show an objective response to systemic treatment.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Capitanio, U. et al. Epidemiology of renal cell carcinoma. Eur. Urol. 75, 74–84 (2019).
Bukowski, R. M. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer 80, 1198–1220 (1997).
Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 353, 14–17 (1999).
Rosenberg, S. A. et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med. 316, 889–897 (1987).
Atzpodien, J., Körfer, A., Franks, C. R., Poliwoda, H. & Kirchner, H. Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet 335, 1509–1512 (1990).
West, W. H. et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N. Engl. J. Med. 316, 898–905 (1987).
Ljungberg, B. et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. Eur. Urol. 75, 799–810 (2019).
NCI. Cancer of the Kidney and Renal Pelvis — Cancer Stat Facts. NIH https://seer.cancer.gov/statfacts/html/kidrp.html (2022).
Patard, J.-J. et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J. Clin. Oncol. 22, 3316–3322 (2004).
Mickisch, G. H., Garin, A., van Poppel, H., de Prijck, L. & Sylvester, R. European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358, 966–970 (2001).
Flanigan, R. C. et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N. Engl. J. Med. 345, 1655–1659 (2001).
Flanigan, R. C. Debulking nephrectomy in metastatic renal cancer. Clin. Cancer Res. 10, 6335S–6341SS (2004).
Turajlic, S. et al. Tracking cancer evolution reveals constrained routes to metastases: TRACERx renal. Cell 173, 581–594.e12 (2018).
Motzer, R. J. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115–124 (2007).
Motzer, R. J. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803–1813 (2015).
Motzer, R. J. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 378, 1277–1290 (2018).
ESMO. eUpdate — renal cell carcinoma treatment recommendations. ESMO https://www.esmo.org/guidelines/genitourinary-cancers/renal-cell-carcinoma/eupdate-renal-cell-carcinoma-treatment-recommendations-3 (2020).
Méjean, A. et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N. Engl. J. Med. 379, 417–427 (2018).
Escudier, B. et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann. Oncol. 30, 706–720 (2019).
Baldewijns, M. M. L., van Vlodrop, I. J. H. & Schouten, L. J. Soetekouw PMMB, de Bruïne AP, van Engeland M. Genetics and epigenetics of renal cell cancer. Biochim. Biophys. Acta 1785, 133–155 (2008).
Motzer, R. J., Bander, N. H. & Nanus, D. M. Renal-cell carcinoma. N. Engl. J. Med. 335, 865–875 (1996).
Buti, S. et al. Chemotherapy in metastatic renal cell carcinoma today? A systematic review. Anticancer Drugs 24, 535–554 (2013).
Escudier, B. et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370, 2103–2111 (2007).
Motzer, R. J. et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 3584–3590 (2009).
Hudes, G. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271–2281 (2007).
Motzer, R. J. et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372, 449–456 (2008).
Motzer, R. J. et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 20, 1370–1385 (2019).
Motzer, R. et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N. Engl. J. Med. 384, 1289–1300 (2021).
Rini, B. I. et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1116–1127 (2019).
Motzer, R. J. et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1103–1115 (2019).
Choueiri, T. K. et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 384, 829–841 (2021).
Akhtar, M., Al-Bozom, I. A., Al & Hussain, T. Molecular and metabolic basis of clear cell carcinoma of the kidney. Adv. Anat. Pathol. 25, 189–196 (2018).
NCBI. VHL von Hippel-Lindau tumor suppressor [Homo sapiens (human)] — Genev — NCBI. NIH https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=ShowDetailView&TermToSearch=7428 (2022).
Kaelin, W. G. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin. Cancer Res. 13, 680s–684ss (2007).
Los, M., Roodhart, J. M. L. & Voest, E. E. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist 12, 443–450 (2007).
Lemmon, M. A. & Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 141, 1117–1134 (2010).
Zwick, E., Bange, J. & Ullrich, A. Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr. Relat. Cancer 8, 161–173 (2001).
Robinson, C. J. & Stringer, S. E. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J. Cell Sci. 114, 853–865 (2001).
Porter, A. C. & Vaillancourt, R. R. Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis. Oncogene 17, 1343–1352 (1998).
Escudier, B. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125–134 (2007).
Sternberg, C. N. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J. Clin. Oncol. 28, 1061–1068 (2010).
Rini, B. I. et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378, 1931–1939 (2011).
Motzer, R. J. et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 16, 1473–1482 (2015).
Rini, B. I. et al. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. Lancet Oncol. 21, 95–104 (2020).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03680521 (2021).
Cohen, R. B. & Oudard, S. Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities. Invest. N. Drugs 30, 2066–2079 (2012).
Kollmannsberger, C. Sunitinib side effects as surrogate biomarkers of efficacy. Can. Urol. Assoc. J. 10, S245–S247 (2016).
Hay, N. & Sonenberg, N. Upstream and downstream of mTOR. Genes. Dev. 18, 1926–1945 (2004).
Yin, Y. et al. mTORC2 promotes type I insulin-like growth factor receptor and insulin receptor activation through the tyrosine kinase activity of mTOR. Cell Res. 26, 46–65 (2016).
Faes, S., Demartines, N. & Dormond, O. Mechanistic target of rapamycin inhibitors in renal cell carcinoma: potential, limitations, and perspectives. Front. Cell Dev. Biol. 9, 636037 (2021).
Loewith, R. et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol. Cell 10, 457–468 (2002).
Albiges, L. et al. Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma. Ann. Oncol. 23, 1943–1953 (2012).
Rodriguez-Pascual, J., Cheng, E., Maroto, P. & Duran, I. Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma. Anticancer Drugs 21, 478–486 (2010).
Penttilä, P. et al. Everolimus-induced pneumonitis associates with favourable outcome in patients with metastatic renal cell carcinoma. Eur. J. Cancer 81, 9–16 (2017).
Braun, D. A. et al. Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell 39, 632–648.e8 (2021).
Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252–264 (2012).
Zhang, Y. & Zheng, J. Functions of immune checkpoint molecules beyond immune evasion. Adv. Exp. Med. Biol. 1248, 201–226 (2020).
Iwai, Y., Hamanishi, J., Chamoto, K. & Honjo, T. Cancer immunotherapies targeting the PD-1 signaling pathway. J. Biomed. Sci. 24, 26 (2017).
Walunas, T. L. et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1, 405–413 (1994).
Qureshi, O. S. et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 332, 600–603 (2011).
Carlo, M. I., Voss, M. H. & Motzer, R. J. Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma. Nat. Rev. Urol. 13, 420–431 (2016).
Iwai, Y. et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl Acad. Sci. USA 99, 12293–12297 (2002).
Boussiotis, V. A. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N. Engl. J. Med. 375, 1767–1778 (2016).
Agata, Y. et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol. 8, 765–772 (1996).
Okazaki, T. & Honjo, T. PD-1 and PD-1 ligands: from discovery to clinical application. Int. Immunol. 19, 813–824 (2007).
Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23–34 (2015).
Comin-Anduix, B., Escuin-Ordinas, H. & Ibarrondo, F. J. Tremelimumab: research and clinical development. Onco Targets Ther. 9, 1767–1776 (2016).
Massard, C. et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J. Clin. Oncol. 34, 3119–3125 (2016).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03288532 (2020).
Drugs.com. Pembrolizumab monograph for professionals. Drugs.com https://www.drugs.com/monograph/pembrolizumab.html (2021).
Choueiri, T. K. et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N. Engl. J. Med. 385, 683–694 (2021).
AdisInsight. Toripalimab — Shanghai Junshi Biosciences — AdisInsight. AdisInsight https://adisinsight.springer.com/drugs/800046697 (2022).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04385654 (2020).
Rini, B. I. et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet 393, 2404–2415 (2019).
Drugs.com. Avelumab monograph for professionals. Drugs.com https://www.drugs.com/monograph/avelumab.html (2022).
Weber, J. S., Yang, J. C., Atkins, M. B. & Disis, M. L. Toxicities of immunotherapy for the practitioner. J. Clin. Oncol. 33, 2092–2099 (2015).
Zhou, X. et al. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. BMC Med. 18, 87 (2020).
Postow, M. A., Callahan, M. K. & Wolchok, J. D. Immune checkpoint blockade in cancer therapy. J. Clin. Oncol. 33, 1974–1982 (2015).
EAU. EAU Guidelines: renal cell carcinoma. Uroweb https://uroweb.org/guideline/renal-cell-carcinoma/#note_472 (2022).
Heng, D. Y. C. et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 14, 141–148 (2013).
Heng, D. Y. C. et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J. Clin. Oncol. 27, 5794–5799 (2009).
Ljungberg, B. et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur. Urol. 58, 398–406 (2010).
Albiges, L. et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open. 5, e001079 (2020).
Tannir, N. M. et al. Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma. Clin. Cancer Res. 27, 78–86 (2021).
Shuch, B. et al. Impact of pathological tumour characteristics in patients with sarcomatoid renal cell carcinoma. BJU Int. 109, 1600–1606 (2012).
Cella, D. et al. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. Lancet Oncol. 20, 297–310 (2019).
Powles, T. et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol. 21, 1563–1573 (2020).
Atkins, M. B. et al. Patient-reported outcomes from the phase III randomized IMmotion151 trial: atezolizumab + bevacizumab versus sunitinib in treatment-naïve metastatic renal cell carcinoma. Clin. Cancer Res. 26, 2506–2514 (2020).
Klaassen, Z. ASCO 2021: health-related quality-of-life analysis from the phase 3 CLEAR trial of lenvatinib + pembrolizumab or everolimus versus sunitinib for patients with advanced RCC. Uro Today https://www.urotoday.com/conference-highlights/asco-2021/asco-2021-kidney-cancer/130132-asco-2021-health-related-quality-of-life-analysis-from-the-phase-3-clear-trial-of-lenvatinib-pembrolizumab-or-everolimus-versus-sunitinib-for-patients-with-advanced-rcc.amp.html (2021).
Bedke, J. et al. The 2021 updated European Association of Urology Guidelines on renal cell carcinoma: immune checkpoint inhibitor-based combination therapies for treatment-naive metastatic clear-cell renal cell carcinoma are standard of care. Eur. Urol. 80, 393–397 (2021).
Law, T. M. et al. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 76, 824–832 (1995).
O’Neill, L. A. J., Kishton, R. J. & Rathmell, J. A guide to immunometabolism for immunologists. Nat. Rev. Immunol. 16, 553–565 (2016).
Bhindi, B. et al. Systematic review of the role of cytoreductive nephrectomy in the targeted therapy era and beyond: an individualized approach to metastatic renal cell carcinoma. Eur. Urol. 75, 111–128 (2019).
Posadas, E. M. & Figlin, R. A. Kidney cancer: progress and controversies in neoadjuvant therapy. Nat. Rev. Urol. 11, 254–255 (2014).
Rini, B. I. et al. A phase II study of pazopanib in patients with localized renal cell carcinoma to optimize preservation of renal parenchyma. J. Urol. 194, 297–303 (2015).
Cai, W. et al. Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study. Cancer Commun. 39, 56 (2019).
Hatiboglu, G. et al. Effective downsizing but enhanced intratumoral heterogeneity following neoadjuvant sorafenib in patients with non-metastatic renal cell carcinoma. Langenbecks Arch. Surg. 402, 637–644 (2017).
Lebacle, C. et al. Evaluation of axitinib to downstage cT2a renal tumours and allow partial nephrectomy: a phase II study. BJU Int. 123, 804–810 (2019).
Silberstein, J. L. et al. Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery. BJU Int. 106, 1270–1276 (2010).
Roy, A. M., Briggler, A., Tippit, D., Dawson, K. & Verma, R. Neoadjuvant cabozantinib in renal-cell carcinoma: a brief review. Clin. Genitourin. Cancer 18, e688–e691 (2020).
Cowey, C. L. et al. Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J. Clin. Oncol. 28, 1502–1507 (2010).
Field, C. A. et al. Neoadjuvant sunitinib decreases inferior vena caval thrombus size and is associated with improved oncologic outcomes: a multicenter comparative analysis. Clin. Genitourin. Cancer 17, e505–e512 (2019).
Bex, A. et al. Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. World J. Urol. 27, 533–539 (2009).
Bigot, P. et al. Neoadjuvant targeted molecular therapies in patients undergoing nephrectomy and inferior vena cava thrombectomy: is it useful? World J. Urol. 32, 109–114 (2014).
Karam, J. A. et al. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma. Eur. Urol. 66, 874–880 (2014).
Hellenthal, N. J. et al. Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. J. Urol. 184, 859–864 (2010).
Thomas, A. A. et al. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J. Urol. 181, 518–523 (2009). discussion 523.
Zhang, Y. et al. Sorafenib neoadjuvant therapy in the treatment of high risk renal cell carcinoma. PLoS One 10, e0115896 (2015).
Rini, B. I. et al. The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgery. J. Urol. 187, 1548–1554 (2012).
Cost, N. G. et al. The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. Eur. Urol. 59, 912–918 (2011).
van der Veldt, A. A. M. et al. Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clin. Cancer Res. 14, 2431–2436 (2008).
Hutson, T. E., Thoreson, G. R., Figlin, R. A. & Rini, B. I. The evolution of systemic therapy in metastatic renal cell carcinoma. Am. Soc. Clin. Oncol. Educ. Book. 35, 113–117 (2016).
Choueiri, T. K. et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1814–1823 (2015).
Therasse, P. et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst. 92, 205–216 (2000).
AUA. Renal Cancer: renal mass & localized renal cancer guideline. AUA https://www.auanet.org/guidelines/guidelines/renal-cancer-renal-mass-and-localized-renal-cancer-guideline (2017).
Russo, P. Oncological and renal medical importance of kidney-sparing surgery. Nat. Rev. Urol. 10, 292–299 (2013).
Van Poppel, H. et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur. Urol. 59, 543–552 (2011).
Lane, B. R. et al. Presurgical sunitinib reduces tumor size and may facilitate partial nephrectomy in patients with renal cell carcinoma. Urol. Oncol. 33, 112.e15–21 (2015).
Kutikov, A. & Uzzo, R. G. The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J. Urol. 182, 844–853 (2009).
Pfizer. SUTENT prescribing information. Pfizer http://labeling.pfizer.com/showlabeling.aspx?id=607 (2006).
Minami, H. et al. Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. Cancer Sci. 99, 1492–1498 (2008).
Mootha, R. K., Butler, R., Laucirica, R., Scardino, P. T. & Lerner, S. P. Renal cell carcinoma with an infrarenal vena caval tumor thrombus. Urology 54, 561 (1999).
Neves, R. J. & Zincke, H. Surgical treatment of renal cancer with vena cava extension. Br. J. Urol. 59, 390–395 (1987).
Karnes, R. J. & Blute, M. L. Surgery insight: management of renal cell carcinoma with associated inferior vena cava thrombus. Nat. Clin. Pract. Urol. 5, 329–339 (2008).
Labbate, C. et al. Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy. J. Immunother. Cancer 7, 66 (2019).
Singla, N. et al. Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma. Urol. Oncol. 37, 924–931 (2019).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02212730 (2020).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02575222 (2020).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02595918 (2020).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02762006 (2020).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03055013 (2022).
Dall’Olio, F. G. et al. Immortal time bias in the association between toxicity and response for immune checkpoint inhibitors: a meta-analysis. Immunotherapy 13, 257–270 (2021).
Bex, A. et al. Efficacy, safety, and biomarker analysis of neoadjuvant avelumab/axitinib in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy (NeoAvAx). J. Clin. Oncol. 40, 289–289 (2022).
Pizzocaro, G. et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J. Clin. Oncol. 19, 425–431 (2001).
Messing, E. M. et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J. Clin. Oncol. 21, 1214–1222 (2003).
Clark, J. I. et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J. Clin. Oncol. 21, 3133–3140 (2003).
Passalacqua, R. et al. Adjuvant low-dose interleukin-2 (IL-2) plus interferon-α (IFN-α) in operable renal cell carcinoma (RCC): a phase III, randomized, multicentre trial of the Italian Oncology Group for Clinical Research (GOIRC). J. Immunother. 37, 440–447 (2014).
Jocham, D. et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 363, 594–599 (2004).
Janowitz, T., Welsh, S. J., Zaki, K., Mulders, P. & Eisen, T. Adjuvant therapy in renal cell carcinoma-past, present, and future. Semin. Oncol. 40, 482–491 (2013).
Janzen, N. K., Kim, H. L., Figlin, R. A. & Belldegrun, A. S. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol. Clin. North. Am. 30, 843–852 (2003).
Porta, C. et al. The adjuvant treatment of kidney cancer: a multidisciplinary outlook. Nat. Rev. Nephrol. 15, 423–433 (2019).
Haas N. B., Uzzo R. G. Perioperative therapy in renal cell carcinoma: what do we know, what have we learned, what’s next? J. Clin. Oncol. 36, 3608–3614 (2018).
Figlin, R. A., Leibovich, B. C., Stewart, G. D. & Negrier, S. Adjuvant therapy in renal cell carcinoma: does higher risk for recurrence improve the chance for success? Ann. Oncol. 29, 324–331 (2018).
Frank, I. et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J. Urol. 168, 2395–2400 (2002).
Leibovich, B. C. et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 97, 1663–1671 (2003).
Zisman, A. et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J. Clin. Oncol. 19, 1649–1657 (2001).
Cortellini, A. et al. Predictive ability for disease-free survival of the GRade, Age, Nodes, and Tumor (GRANT) score in patients with resected renal cell carcinoma. Curr. Urol. 14, 98–104 (2020).
Brooks, S. A. et al. ClearCode34: a prognostic risk predictor for localized clear cell renal cell carcinoma. Eur. Urol. 66, 77–84 (2014).
Rini, B. et al. A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies. Lancet Oncol. 16, 676–685 (2015).
Ingels A., et al. Vimentin over-expression and carbonic anhydrase IX under-expression are independent predictors of recurrence, specific and overall survival in non-metastatic clear-cell renal carcinoma: a validation study. World J. Urol. 35, 81–87 (2016)
Haas, N. B. et al. Adjuvant treatment for high-risk clear cell renal cancer: updated results of a high-risk subset of the ASSURE randomized trial. JAMA Oncol. 3, 1249–1252 (2017).
Motzer, R. J. et al. Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma. J. Clin. Oncol. 35, 3916–3923 (2017).
Gross-Goupil M., et al. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial. Ann. Oncol. 29, 2371–2378 (2018).
Ravaud, A. et al. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N. Engl. J. Med. 375, 2246–2254 (2016).
Motzer, R. J. et al. Adjuvant sunitinib for high-risk renal cell carcinoma after nephrectomy: subgroup analyses and updated overall survival results. Eur. Urol. 73, 62–68 (2018).
Larroquette, M. et al. Adjuvant therapy in renal cell carcinoma: current knowledges and future perspectives. Cancer Treat. Rev. 97, 102207 (2021).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/record/NCT01120249 (2021).
Sun, M. et al. Adjuvant vascular endothelial growth factor-targeted therapy in renal cell carcinoma: a systematic review and pooled analysis. Eur. Urol. 74, 611–620 (2018).
Escudier, B. et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 25, iii49–iii56 (2014).
Rini, B. I. et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). J. Immunother. Cancer 7, 354 (2019).
Palumbo, C. et al. A plea for optimizing selection in current adjuvant immunotherapy trials for high-risk nonmetastatic renal cell carcinoma according to expected cancer-specific mortality. Clin. Genitourin. Cancer 18, 314–321.e1 (2020).
Eggermont, A. M. M. et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 16, 522–530 (2015).
Weber, J. et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N. Engl. J. Med. 377, 1824–1835 (2017).
Bajorin, D. F. et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N. Engl. J. Med. 384, 2102–2114 (2021).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03024996 (2022).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03138512 (2022).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03142334 (2021).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03055013 (2022).
Harshman, L. C. et al. Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: a trial-level meta-analysis. Cancer 124, 925–933 (2018).
FDA. Renal cell carcinoma: developing drugs and biologics for adjuvant treatment. FDA https://www.fda.gov/regulatory-information/search-fda-guidance-documents/renal-cell-carcinoma-developing-drugs-and-biologics-adjuvant-treatment (2020).
Bedke, J. et al. 2021 Updated European Association of Urology guidelines on the use of adjuvant pembrolizumab for renal cell carcinoma. Eur. Urol. 82, 134–137 (2021).
Martinez Chanza, N., Tripathi, A. & Harshman, L. C. Adjuvant therapy options in renal cell carcinoma: where do we stand? Curr. Treat. Options Oncol. 20, 44 (2019).
Mazzaschi, G., Quaini, F., Bersanelli, M. & Buti, S. Cytoreductive nephrectomy in the era of targeted- and immuno-therapy for metastatic renal cell carcinoma: an elusive issue? A systematic review of the literature. Crit. Rev. Oncol. Hematol. 160, 103293 (2021).
Culp, S. H. et al. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer 116, 3378–3388 (2010).
Rini, B. I., Campbell, S. C. & Escudier, B. Renal cell carcinoma. Lancet 373, 1119–1132 (2009).
Bex, A. et al. Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial. JAMA Oncol. 5, 164–170 (2019).
Roussel, E. et al. Rates and predictors of perioperative complications in cytoreductive nephrectomy: analysis of the registry for metastatic renal cell carcinoma. Eur. Urol. Oncol. 3, 523–529 (2020).
Choueiri, T. K. et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J. Urol. 185, 60–66 (2011).
Motzer, R. J. et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. 17, 2530–2540 (1999).
De Bruijn, R. E. et al. Surgical safety of cytoreductive nephrectomy following sunitinib: results from the multicentre, randomised controlled trial of immediate versus deferred nephrectomy (SURTIME). Eur. Urol. 76, 437–440 (2019).
Méjean, A. et al. Sunitinib alone or after nephrectomy for patients with metastatic renal cell carcinoma: is there still a role for cytoreductive nephrectomy? Eur. Urol. 80, 417–424 (2021).
Rini, B. I. et al. Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. Lancet Oncol. 17, 1317–1324 (2016).
Roussel E., et al. Too good for CARMENA: criteria associated with long systemic therapy free intervals post cytoreductive nephrectomy for metastatic clear cell renal cell carcinoma. Scand. J. Urol. 54, 493-499 (2020).
Mason, R. J. et al. Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma. Can. Urol. Assoc. J. 13, 166–174 (2019).
Bex, A. et al. Updated European Association of Urology guidelines for cytoreductive nephrectomy in patients with synchronous metastatic clear-cell renal cell carcinoma. Eur. Urol. 74, 805–809 (2018).
Motzer, R. J. et al. NCCN guidelines insights: kidney cancer, version 1.2021. J. Natl Compr. Cancer Netw. 18, 1160–1170 (2020).
Motzer, R. J. & Russo, P. Cytoreductive nephrectomy — patient selection is key. N. Engl. J. Med. 379, 481–482 (2018).
Larcher, A. et al. Cytoreductive nephrectomy in metastatic patients with signs or symptoms: implications for renal cell carcinoma guidelines. Eur. Urol. 78, 321–326 (2020).
Larcher, A. et al. Individualised indications for cytoreductive nephrectomy: which criteria define the optimal candidates? Eur. Urol. Oncol. 2, 365–378 (2019).
Mejean, A. et al. Cytoreductive nephrectomy (CN) in metastatic renal cancer (mRCC): update on Carmena trial with focus on intermediate IMDC-risk population. J. Clin. Oncol. 37, 4508–4508 (2019).
Bhindi, B. et al. Deferred cytoreductive nephrectomy in patients with newly diagnosed metastatic renal cell carcinoma. Eur. Urol. 78, 615–623 (2020).
Méjean, A. Primum non nocere: when nephrectomy becomes a selective approach in metastatic renal cell carcinoma. Eur. Urol. Oncol. 3, 174–175 (2020).
Albiges, L. et al. Updated European Association of Urology guidelines on renal cell carcinoma: immune checkpoint inhibition is the new backbone in first-line treatment of metastatic clear-cell renal cell carcinoma. Eur. Urol. 76, 151–156 (2019).
Liu, J. et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov. 6, 1382–1399 (2016).
Kinsey, E. N. & George, D. Can I get a multidisciplinary consult, please? Systemic immunotherapy and the timing of cytoreductive nephrectomy. Eur. Urol. Focus 6, 9–10 (2020).
Bakouny, Z. et al. Cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or targeted therapy (TT): a propensity score-based analysis. J. Clin. Oncol. 38, 608 (2020).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03977571 (2020).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04510597 (2021).
Jonasch, E. et al. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 4076–4081 (2009).
Powles, T. et al. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer. Eur. Urol. 60, 448–454 (2011).
Bex, A. et al. A phase II, single-arm trial of neoadjuvant axitinib plus avelumab in patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (NEOAVAX). Future Oncol. 15, 2203–2209 (2019).
Reimers, M. A. et al. Elective cytoreductive nephrectomy after checkpoint inhibitor immunotherapy in patients with initially unresectable metastatic clear cell renal cell carcinoma. Clin. Genitourin. Cancer 18, 361–366 (2020).
Pignot, G. et al. Nephrectomy after complete response to immune checkpoint inhibitors for metastatic renal cell carcinoma: a new surgical challenge? Eur. Urol. 77, 761–763 (2020).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02210117(2020).
Epaillard, N. et al. BIONIKK: a phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer. Bull. Cancer 107, eS22–eS27 (2020).
Beuselinck, B. et al. Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting. Clin. Cancer Res. 21, 1329–1339 (2015).
Roussel, E. et al. Molecular subtypes and gene expression signatures as prognostic features in fully resected clear cell renal cell carcinoma: a tailored approach to adjuvant trials. Clin. Genitourin. Cancer 19, e382–e394 (2021).
McDermott, D. F. et al. Publisher correction: clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat. Med. 24, 1941 (2018).
Najjar, Y. G. et al. Myeloid-derived suppressor cell subset accumulation in renal cell carcinoma parenchyma is associated with intratumoral expression of IL1β, IL8, CXCL5, and Mip-1α. Clin. Cancer Res. 23, 2346–2355 (2017).
Osada, T. et al. The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol. Immunother. 57, 1115–1124 (2008).
Hannan, R. et al. Phase II trial of stereotactic ablative radiation (SAbR) for oligometastatic kidney cancer. J. Clin. Oncol. 39, 311–311 (2021).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04090710 (2022).
Jadvar, H., Chen, X., Cai, W. & Mahmood, U. Radiotheranostics in cancer diagnosis and management. Radiology. 286, 388–400 (2018).
Courcier, J. et al. Carbonic anhydrase IX in renal cell carcinoma, implications for disease management. Int. J. Mol. Sci. 21, E7146 (2020).
Muselaers, C. H. J. et al. Phase 2 study of lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma. Eur. Urol. 69, 767–770 (2016).
Filetti, S. et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann. Oncol. 30, 1856–1883 (2019).
Hofman, M. S. et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet 397, 797–804 (2021).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04118855 (2019).
Motzer, R. J., Bacik, J., Murphy, B. A., Russo, P. & Mazumdar, M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. 20, 289–296 (2002).
de Velasco, G. et al. A case series of advanced renal cell carcinoma patients treated with neoadjuvant cabozantinib prior to cytoreductive nephrectomy within the phase 2 CABOPRE trial. Oncotarget. 11, 4457–4462 (2020).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04393350 (2022).
Acknowledgements
This work was carried out on behalf of the YAU working group.
Author information
Authors and Affiliations
Contributions
A.I., D.A., R.B., R.C., U. Carbonara, S.E., Ö.K., T.K., M.C.K., M.M., M.C.M., I.O., A.P. and E.R. researched data for the article. A.I., R.B., R.C., U. Capitanio, S.E., Ö.K., T.K., M.C.K., M.C.M., I.O., N.P. and E.R. made substantial contributions to the discussion of content. A.I., D.A., R.B., R.C., U. Carbonara, S.E., Ö.K., T.K., M.C.K., M.M., M.C.M., I.O. and E.R. wrote the article. A.I., D.A., R.B., R.C., U. Capitanio, S.E., Ö.K., U. Carbonara, T.K., M.C.K., M.M., M.C.M., N.P., A.P., E.R. and A.D.L.T. reviewed and edited the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
A.I. declares competing interests with Intuitive Surgical, Ipsen, Bristol-Myers Squibb, Pfizer and Elypta. D.A. declares competing interests with Elypta. R.C. declares competing interests with Elypta, Janssen and Merck. E.R. declares competing interests with Pfizer and Ipsen. The other authors declare no competing interests.
Peer review
Peer review information
Nature Reviews Urology thanks E. Jonasch, S. Buti, M. Staehler and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Glossary
- FKSI-19
-
A validated 19-item instrument that measures tumour-specific patient-reported outcomes (PROs) in patients with kidney cancer and contains several domains (disease-related symptoms, disease-related symptoms physical, disease-related symptoms emotional, treatment side effects, and functional well-being); patients rate their symptoms on a five-point scale with responses ranging from “not at all” to “very much”. The FKSI-19 total score is based on all 19 items and ranges from 0 to 76, with a high score indicating few symptoms; a change ≥3 points has been established as a clinically important difference.
- EQ-5D-3L
-
A validated, standardized instrument for measuring general health status that includes five domains: mobility; self-care; usual activities; pain and discomfort; and depression and anxiety. Patients self-rate their health state on a visual 100-point analogue rating scale, with zero being the worst health imaginable and 100 the best health imaginable. An EQ-5D-3L health-state utility index score ranging from 0 to 1 is calculated for each of the health states described by the instrument on the basis of values provided in large general population studies.
- Simon’s two-stage design
-
Simon’s two-stage design is a type of phase II clinical trial. It is one of the most common multi-stage designs used in phase IIa clinical trials. Simon’s two-stage design is an exact design, which enables flexibility regarding the null and alternative hypotheses, also enabling stopping for futility.
Rights and permissions
About this article
Cite this article
Ingels, A., Campi, R., Capitanio, U. et al. Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma. Nat Rev Urol 19, 391–418 (2022). https://doi.org/10.1038/s41585-022-00592-3
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-022-00592-3
This article is cited by
-
VHL-HIF-2α axis-induced SEMA6A upregulation stabilized β-catenin to drive clear cell renal cell carcinoma progression
Cell Death & Disease (2023)
-
Nanocomposite pastes of gelatin and cyclodextrin-grafted chitosan nanoparticles as potential postoperative tumor therapy
Advanced Composites and Hybrid Materials (2023)
-
APOA1 mRNA and protein in kidney renal clear cell carcinoma correlate with the disease outcome
Scientific Reports (2022)